Literature DB >> 20379784

Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC Melanoma Database.

Seng-jaw Soong1, Shouluan Ding, Daniel Coit, Charles M Balch, Jeffrey E Gershenwald, John F Thompson, Phyllis Gimotty.   

Abstract

BACKGROUND: We sought to develop a reliable and reproducible statistical model to predict the survival outcome of patients with localized melanoma.
METHODS: A total of 25,734 patients with localized melanoma from the 2008 American Joint Committee on Cancer (AJCC) Melanoma Database were used for the model development and validation. The predictive model was developed from the model development data set (n = 14,760) contributed by nine major institutions and study groups and was validated on an independent model validation data set (n = 10,974) consisting of patients from a separate melanoma center. Multivariate analyses based on the Cox model were performed for the model development, and the concordance correlation coefficients were calculated to assess the adequacy of the predictive model.
RESULTS: Patient characteristics in both data sets were virtually identical, and tumor thickness was the single most important prognostic factor. Other key prognostic factors identified by stratified analyses included ulceration, lesion site, and patient age. Direct comparisons of the predicted 5- and 10-year survival rates calculated from the predictive model and the observed Kaplan-Meier 5- and 10-year survival rates estimated from the validation data set yielded high concordance correlation coefficients of 0.90 and 0.93, respectively. A Web-based electronic prediction tool was also developed ( http://www.melanomaprognosis.org/ ).
CONCLUSIONS: This is the first predictive model for localized melanoma that was developed based on a very large data set and was successfully validated on an independent data set. The high concordance correlation coefficients demonstrated the accuracy of the predicted model. This predictive model provides a clinically useful tool for making treatment decisions, for assessing patient risk, and for planning and analyzing clinical trials.

Entities:  

Mesh:

Year:  2010        PMID: 20379784     DOI: 10.1245/s10434-010-1050-z

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  34 in total

1.  Histological ulceration as a prognostic factor in cutaneous melanoma: a study of 423 cases in Spain.

Authors:  José Antonio Avilés-Izquierdo; Pablo Lázaro-Ochaita
Journal:  Clin Transl Oncol       Date:  2012-03       Impact factor: 3.405

Review 2.  Molecular pathology of cutaneous melanoma.

Authors:  Léon C van Kempen; Margaret Redpath; Caroline Robert; Alan Spatz
Journal:  Melanoma Manag       Date:  2014-12-04

Review 3.  Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care.

Authors:  Richard A Scolyer; Georgina V Long; John F Thompson
Journal:  Mol Oncol       Date:  2011-03-21       Impact factor: 6.603

4.  Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases.

Authors:  Charles M Balch; Jeffrey E Gershenwald; Seng-Jaw Soong; John F Thompson; Shouluan Ding; David R Byrd; Natale Cascinelli; Alistair J Cochran; Daniel G Coit; Alexander M Eggermont; Timothy Johnson; John M Kirkwood; Stanley P Leong; Kelly M McMasters; Martin C Mihm; Donald L Morton; Merrick I Ross; Vernon K Sondak
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

5.  Age as a prognostic factor in patients with localized melanoma and regional metastases.

Authors:  Charles M Balch; Seng-jaw Soong; Jeffrey E Gershenwald; John F Thompson; Daniel G Coit; Michael B Atkins; Shouluan Ding; Alistair J Cochran; Alexander M M Eggermont; Keith T Flaherty; Phyllis A Gimotty; Timothy M Johnson; John M Kirkwood; Stanley P Leong; Kelly M McMasters; Martin C Mihm; Donald L Morton; Merrick I Ross; Vernon K Sondak
Journal:  Ann Surg Oncol       Date:  2013-07-10       Impact factor: 5.344

Review 6.  Tissue prognostic biomarkers in primary cutaneous melanoma.

Authors:  Mario Mandalà; Daniela Massi
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

Review 7.  Staging and prognosis of cutaneous melanoma.

Authors:  Paxton V Dickson; Jeffrey E Gershenwald
Journal:  Surg Oncol Clin N Am       Date:  2011-01       Impact factor: 3.495

8.  Melanoma to the heart.

Authors:  Charis G Durham; James A Hall; Erica J Fidone; Ryan Mack; Austin L Metting
Journal:  Proc (Bayl Univ Med Cent)       Date:  2016-10

9.  The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.

Authors:  Howard L Kaufman; John M Kirkwood; F Stephen Hodi; Sanjiv Agarwala; Thomas Amatruda; Steven D Bines; Joseph I Clark; Brendan Curti; Marc S Ernstoff; Thomas Gajewski; Rene Gonzalez; Laura Jane Hyde; David Lawson; Michael Lotze; Jose Lutzky; Kim Margolin; David F McDermott; Donald Morton; Anna Pavlick; Jon M Richards; William Sharfman; Vernon K Sondak; Jeffrey Sosman; Susan Steel; Ahmad Tarhini; John A Thompson; Jill Titze; Walter Urba; Richard White; Michael B Atkins
Journal:  Nat Rev Clin Oncol       Date:  2013-08-27       Impact factor: 66.675

10.  Vitamin D receptor polymorphisms and survival in patients with cutaneous melanoma: a population-based study.

Authors:  Irene Orlow; Anne S Reiner; Nancy E Thomas; Pampa Roy; Peter A Kanetsky; Li Luo; Susan Paine; Bruce K Armstrong; Anne Kricker; Loraine D Marrett; Stefano Rosso; Roberto Zanetti; Stephen B Gruber; Hoda Anton-Culver; Richard P Gallagher; Terence Dwyer; Klaus Busam; Colin B Begg; Marianne Berwick
Journal:  Carcinogenesis       Date:  2015-10-31       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.